<DOC>
	<DOCNO>NCT01736904</DOCNO>
	<brief_summary>The aim study compare weekly-XELIRI ( wXELIRI ) regimen versus FOLFIRI regimen treatment advance colorectal cancer patient . The hypothesis efficacy wXELIRI less FOLFIRI tolerable toxicity .</brief_summary>
	<brief_title>wXELIRI Versus FOLFIRI Regimen Treatment Advanced Colorectal Cancer Patients</brief_title>
	<detailed_description>The combination irinotecan fluorouracil drug regimen frequently use patient advanced colorectal cancer . According previous data , high rate diarrhea observe combination irinotecan capecitabine ( XELIRI ) regimen , compare combination irinotecan 5-fluorouracil ( FOLFIRI ) regimen . However , modify weekly XELIRI regimen , investigate previous single arm study , show tolerate toxicity compare FOLFIRI , without compromise efficacy . It suppose wXELIRI regimen less less FOLFIRI regimen efficacy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Secondline treatment advance colorectal cancer , irinotecan previously use . Age range 1870 year old ECOG performance status 01 Life expectancy 3 month Adequate organ function Previous serious cardiac disease History malignancies except cure basal cell carcinoma skin carcinoma insitu uterine cervix Pregnant lactate woman chronic inflammatory bowel disease intestinal obstruction Serious uncontrolled disease intercurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>advanced colorectal cancer</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>XELIRI</keyword>
</DOC>